EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity

Jia Wu, Jiali Cheng, Li Zhu, Qiang Gao, Haolong Lin, Yuhao Zeng, Yong Li, Weini Li, Ning An, Liang Huang, Min Xiao, Dengju Li und 1 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2025-012243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Jia Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: CD5 Antigens, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Tongji Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for certain hematologic malignancies, therapeutic resistance and disease relapse highlight the critical need to improve the durability of clinical responses. The limited in vivo persistence and antitumor efficacy of CAR-T cells remain major barriers to achieving sustained therapeutic outcomes. Although CD5 has been extensively studied as a therapeutic target in cancers, particularly T-cell malignancies, its role as an immunomodulatory molecule in T cell-based immunotherapy remains poorly understood. Here, we developed a CD5-deficient T cell-based immunotherapy using the CRISPR-Cas9 system to address these limitations and enhance antitumor potency.

Methods

Employing green fluorescent protein knock-in murine models alongside clinical specimens, we examined the in vivo persistence of CD5-deficient T cells and their influence on T-cell receptor (TCR) clonality diversity. The antitumor efficacy of CD5-deficient engineered T cells was assessed in tumor cell line-derived xenograft murine models. To elucidate underlying mechanisms, we performed a comprehensive evaluation of the activation, expansion and infiltration of CD5-deficient engineered T cells in response to antigen stimulation, as well as their exhaustion dynamics under conditions of repeated antigen exposure.

Results

Our study identifies CD5 as a bona fide inhibitory immunomodulatory molecule. CD5 ablation significantly enhances T cell functionality by enhancing the activation level, mitigating exhaustion, promoting CD8 + T cell expansion, and improving in vivo persistence. Single-cell transcriptomic profiling of patient-derived CD5-deficient T cells revealed distinct effector subsets with elevated cytotoxicity markers and cell cycle regulators, such as STMN1, which correlate with enhanced expansion while preserving clonal diversity, as evidenced by TCR repertoire analysis.

Conclusions

These collective findings establish CD5 ablation as a viable strategy to circumvent the intrinsic limitations of current T cell-based therapies, providing a mechanistic rationale for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD5 AntigensImmunotherapy, AdoptiveT-LymphocytesAnimalsMiceHumansCell Line, TumorXenograft Model Antitumor AssaysCytotoxicity, Immunologic

Stichwörter der Autor:innen

Adoptive cell therapy - ACTImmune modulatoryImmunotherapyT cell

Substanzen

CD5 Antigens

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Department of Medicine, Division of General Internal Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Biomedical Science, Cedars-Sinai Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China muweicelltherapy@163.com lidengju@tjh.tjmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Tongji Hospital

Zitieren

APA

Wu, J., Cheng, J., Zhu, L., Gao, Q., Lin, H., Zeng, Y., Li, Y., Li, W., An, N., Huang, L., Xiao, M., Li, D., & Mu, W. (2025). CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012243

Vancouver

Wu J, Cheng J, Zhu L, Gao Q, Lin H, Zeng Y, et al. CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-012243

BibTeX
@article{Wu2025,
  author = {Wu, Jia and Cheng, Jiali and Zhu, Li and Gao, Qiang and Lin, Haolong and Zeng, Yuhao and Li, Yong and Li, Weini and An, Ning and Huang, Liang and Xiao, Min and Li, Dengju and Mu, Wei},
  title = {CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2025-012243}
}
Kostenlos starten →